Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
ICMR will continue to track trends in HMPV circulation throughout the year
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Subscribe To Our Newsletter & Stay Updated
